SUNNYVALE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the second quarter of 2025 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2025 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following managementâs formal remarks, there will be a question-and-answer session.
Related Questions
What were the key financial metrics (revenue, net loss, cash burn) for Q2 2025, and how do they compare to the company's guidance and prior quarters?
What specific clinical trial milestones or regulatory updates were highlighted, and what is their expected impact on future cash flow?
How did the company's operating expenses and R&D spend change versus expectations, and what does that indicate about burn rate?
What is the current cash runway given the reported cash balance and burn rate, and are there any plans for additional financing?
Did the company announce any new partnerships, licensing deals, or collaborations that could affect valuation?
How does the Q2 2025 performance compare to peer companies in the cardiovascular and pulmonary cellâtherapy space?
What guidance, if any, did management provide for Q3 2025 and the fullâyear 2025 outlook?
Were there any notable changes in the capital structure, such as share issuances, debt financing, or stock option activity?
What were the market reactions during the conference call Q&A, and were there any redâflag concerns raised by analysts?
How might the reported results influence shortâterm technical indicators and trading volume for BCDA?